Healthcare Costs and Resource Utilization Associated with the Use of Empagliflozin Versus Other Antihyperglycemic Agents Among Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease: A Real-World Retrospective Cohort Analysis.

Raju, Aditya; Pimple, Pratik; Stafkey-Mailey, Dana; Farrelly, Eileen; Shetty, Sharash

Healthcare Costs and Resource Utilization Associated with the Use of Empagliflozin Versus Other Antihyperglycemic Agents Among Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease: A Real-World Retrospective Cohort Analysis.

Raju, Aditya; Pimple, Pratik; Stafkey-Mailey, Dana; Farrelly, Eileen; Shetty, Sharash.

Affiliation

Raju A; Xcenda LLC, Carrollton, TX, USA. aditya.raju@xcenda.com.
Pimple P; Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA.
Stafkey-Mailey D; Xcenda LLC, Carrollton, TX, USA.
Farrelly E; Xcenda LLC, Carrollton, TX, USA.
Shetty S; Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA.

Diabetes Ther ; 13(1): 25-42, 2022 Jan.

Article de En | MEDLINE | ID: mdl-34727356

Mots clés

Cardiovascular disease; Costs; Empagliflozin; Healthcare resource utilization; Type 2 diabetes mellitus

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Type d'étude: Health_economic_evaluation / Observational_studies / Prognostic_studies / Risk_factors_studies Aspects: Implementation_research Langue: En Journal: Diabetes Ther Année: 2022 Type de document: Article Pays d'affiliation: États-Unis d'Amérique Pays de publication: États-Unis d'Amérique

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google